We are thrilled to unveil our latest innovation: ELAREM™ Ultimate-FD PLUS The gamma irradiated Human Platelet Lysate ELAREM™ Ultimate-FD PLUS is designed to meet the needs of cell manufacturing applications requiring proven viral reduction. As a xeno-free cell culture supplement, ELAREM™ Ultimate-FD PLUS supports the safe and
“Cell culture with Human Platelet Lysate – Recycled blood for new medicine" Regenerative medicine is developing rapidly. And cell cultivation plays a crucial role for the development, especially in stem cell therapy. Therefore, the demand for safe cell culture media is increasing – as a basis
“Cell cultivation: Anticoagulant-free Human Platelet Lysate” About LABO Journal LABO, a German journal for laboratory technology, introduced our new product ELAREM™ Perform-FD PLUS in the article: “Cell cultivation: Anticoagulant-free Human Platelet Lysate”. The LABO journal is specialized in scientific news, inventions and updates concerning the daily lab
“We are driven by the fact that our Human Platelet Lysate accelerates the developments in the treatment of life-threatening diseases." Dr. Hatim Hemeda, CEO About GIT The German GIT Labor-Fachzeitschrift (Lab Journal) just published a company portrait about PL BioScience. The article gives insights into our vision, the
'Accelerating research and discovery' – Human Platelet Lysate in North America 'Accelerating research and discovery'. The mission of the team at Captivate Bio perfectly fits our mission: Providing one solution for all development stages – Human Platelet Lysate. From the beginning, we saw strong synergies between our companies.
Human Platelet Lysate should seriously considered as the new standard "hPL has favorable properties in terms of ethics and scientific practice and should seriously be considered as a new standard cell culture medium substitute". HPL can replace FCS as a protein source This is only one of the
Despite the challenging times, we would like to wish you and your families a happy Easter. We hope that you and your loved ones are healthy and safe. We certainly continue to support your business with our cell culture supplements. We adapted our processes to provide
Fatal disadvantages of FBS shown The essay by Toni Lindl and Gerhard Gstraunthaler demonstrates the fatal disadvantages of Fetal Bovine Serum (FBS). The article published in the German scientific magazine 'Laborjournal' proposes a contemporary cell culture solution: Human Platelet Lysate (hPL). High reproducibility of trial results achieved
PL BioScience will be one of the exhibitors at the German Stem Cell Network (GSCN) Conference in Berlin. The GSCN aims to foster basic and applied stem cell research - so does the conference: Latest findings in stem cell biology will be covered. The conference will be held from
PL BioScience team participates in the AC² Innovation Award ceremony The PL BioScience team participated in the AC² Innovation Award ceremony in the historic city hall of Aachen. During the event, the winner of the award has been announced. PL BioScience was nominated as one of 5
Cell Culture innovation without the need of animal serum Our innovative cell culture media pave the way to a new standard of cell cultivation, without the need of animal serum. Human Platelet Lysate is highly efficient It is highly efficient, resource-preserving and replaces procedures associated with animal suffering:
PL BioScience is mentioned in the local newspaper ‘Aachener Zeitung’ one more time. Prior to the award ceremony on 6 June 2019, PL BioScience is presented in the recent press article as one of the five finalists. Our whole team is delighted about the appreciation and innovative strength
PL BioScience ensures its Good Manufacturing Practice throughout all process steps. We strive to offer high-quality services - from manufacture to the advise of our customers. For that reason, we established a holistic quality management system underlining our own commitment to quality. Recently, our Good Manufacturing
PL BioScience in 'Journal of the Chamber of Industry and Commerce Aachen' (Wirtschaftliche Nachrichten der Industrie- und Handelskammer Aachen) As one of the five finalists of the AC² Innovation Award 2019, we were able to present our patent-protected technologies to the Journal. The recent report pictures our novel cell
PL BioScience's technology in the local newspaper 'Aachener Zeitung'. Our platelet-based technology is one out of five 'technologies of the future' nominated for the AC² Innovation Award 2019 which honours one local laureate with unique innovative strength. 'Aachener Zeitung' has just presented the five finalists which have the opportunity
With our novel 2D and 3D cell culture media, we made it to the final round of the AC² Innovation Award 2019 for the Aachen region. Our technology based on human blood platelets is one out of five 'technologies of the future' nominated for the award.
The five finalists of the AC² Innovation Award 2019 for the Aachen region have just presented their technologies to the jury. Beforehand, the AGIT (Aachen Society for Innovation and Technology Transfer), the chambers and universities selected numerous local companies with innovative strength. We are very pleased to
"We demonstrate that human platelet lysate (hPL) can replace hS in macrophage cultivation [
The state-of-the-art workshop on the use of human Platelet Lysate for cell therapy was sponsored by PL BioScience. The meeting took place 22‐23 March 2018 in Zurich (Switzerland). Currently, the summarising Committee Report was published. The main stakeholders in the hPL area focused on the question: 'How can hPL further
We wish you a joyful Holiday Season and a happy and successful New Year! We are grateful for the confidence of our customers and partners and look forward to joint projects in 2019.
